Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Is More M&A On The Way For Large-Cap Biotechs?
Morgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks
5 Top Stocks Riding Earnings Season To Big Gains (Investor's Business Daily)

In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $101.00 to $113.00.

BMO Capital Markets noted, “We reiterate our Outperform rating on shares of CELG and increase our price target to $113. Review of longer-term estimates suggests that the high end of 2017 EPS guidance of $13-$14 is realistic and that an EPS CAGR of 23%+ should support further multiple expansion. We continue to believe that Abraxane pancreatic cancer data on January 24 will be better than expected, MM-020 frontline data for Revlimid will support front-line filing in Europe, and multiple levers remain available to exceed near-, intermediate- and long-term guidance.”

Celgene Corporation closed on Friday at $96.30.

Latest Ratings for CELG

DateFirmActionFromTo
Jul 2015Morgan StanleyMaintainsEqual-weight
Jul 2015Canaccord GenuityMaintainsBuy
Jul 2015Piper JaffrayMaintainsOverweight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Get Benzinga's Newsletters